# SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma

> **NCT07668570** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 36 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma

## Interventions

- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT)
- **DRUG:** QL1706

## Key facts

- **NCT ID:** NCT07668570
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2029-07
- **Final completion:** 2030-07
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07668570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07668570, "SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07668570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*